Study on Predicting Response to Standard First-Line Treatment in Diffuse Large B-Cell Lymphoma (DLBCL) Patients Using ctDNA Combined With PET

Abroad (travel likely)Recruiting

Conditions

Diffuse Large B-Cell Lymphoma · DLBCL

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Fudan University Shanghai Cancer Center, Shanghai, Shanghai Municipality, China
Contact: Study coordinator (Rong Tao, M.D) · rtao@shca.org.cn · 8621-64175590
Contact: Study coordinator (Wenhao Zhang) · ZWHL98@foxmail.com
Contact: Principal Investigator (Rong Tao, M.D)

Study leads

Rong Tao, M.D
Study Chair
Fudan University

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Efficacy and Safety of Polatuzumab Vedotin in Combination With Zanubrutinib, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone in Patients With Previously Untreated Diffuse Large B-Cell Lymphoma of the MCD/BN2/N1 Subtypes

Diffuse Large B-Cell Lymphoma (DLBCL)

Abroad (travel likely)RecruitingPHASE2

Nanjing, China

Genetic Subtype-matched Targeted Therapy for the Treatment of Newly Diagnosed DLBCL With TP53 Mutation

Diffuse Large B-Cell Lymphoma (DLBCL)

Abroad (travel likely)RecruitingPHASE2

Suzhou, China

A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy

Large B-cell Lymphoma · Lymphoma, B-Cell · Relapsed Non-Hodgkin Lymphoma

Abroad (travel likely)RecruitingPHASE3

Gilbert, United States · Scottsdale, United States

CAR-T Followed by Bispecific Antibodies

Large B-cell Lymphoma · DLBCL - Diffuse Large B Cell Lymphoma

Abroad (travel likely)RecruitingPHASE2

Omaha, United States · Philadelphia, United States